<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568359</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00046786</org_study_id>
    <nct_id>NCT01568359</nct_id>
  </id_info>
  <brief_title>Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors</brief_title>
  <official_title>Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the Calcium homeostasis in adult patients with&#xD;
      uncontrolled acromegaly. The measurements will be repeated 3-6 months after the treatment of&#xD;
      acromegaly (surgical or medical). The control group consists of patients with nonfunctioning&#xD;
      pituitary tumors who will undergo surgical removal.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Calcitriol is the active form of vitamin D. Parathyroid hormone (PTH) is secreted by the&#xD;
      parathyroid glands in the neck. Both these chemicals are responsible for keeping the levels&#xD;
      of calcium and phosphorous normal and also play a role in bone health. They can be measured&#xD;
      in the blood. In some disorders, PTH or calcitriol levels are elevated, which results in&#xD;
      increased calcium absorption from the gut, increased calcium in the bloodstream, and&#xD;
      increased calcium excretion in the urine. Increased calcium in the urine can lead to the&#xD;
      development of kidney stones. Increased calcium in the bloodstream can have adverse effects&#xD;
      on the heart, gut, kidneys, and bones.&#xD;
&#xD;
      Acromegaly is a condition where a pituitary tumor secretes excessive amounts of growth&#xD;
      hormone. Patients with acromegaly have been found to have a higher prevalence of kidney&#xD;
      stones, urinary calcium, and serum calcium when compared to normal adults. The reason for&#xD;
      this is unknown but a suggested mechanism is that growth hormone stimulates the production of&#xD;
      calcitriol or PTH. If this is true, then treatment of acromegaly resulting in lower growth&#xD;
      hormone levels should also result in lower blood and urine calcium levels. The investigators&#xD;
      want to see if patients with acromegaly have high calcitriol, and vitamin D binding protein,&#xD;
      or PTH levels and see if they change after treatment of the condition. The investigators also&#xD;
      want to assess the amount of calcium in the urine, before and after treatment.&#xD;
&#xD;
      Patients with acromegaly may have disorders of bone health. The reason for this is unknown&#xD;
      but a suggested mechanism is that growth hormone affects bone remodeling. The investigators&#xD;
      want to see if patients with acromegaly have abnormal bone markers, specifically PINP, CTX,&#xD;
      and TRAP, and to see if they change after treatment of the condition.&#xD;
&#xD;
      In order to see if the results are specific to patients with acromegaly, the investigators&#xD;
      also want to check these levels in patients who do not have acromegaly, but have a&#xD;
      &quot;nonfunctioning&quot; pituitary tumor. A nonfunctioning pituitary tumor is one that does not&#xD;
      secrete excessive hormones in the bloodstream.&#xD;
&#xD;
      The specific aims of this study are:&#xD;
&#xD;
        1. To describe baseline calcitriol/PTH status in patients with uncontrolled acromegaly.&#xD;
&#xD;
        2. To assess the change in calcitriol/PTH levels after treatment with acromegaly (surgical&#xD;
           or medical).&#xD;
&#xD;
        3. To evaluate the calcium and calcitriol/PTH levels in patients with acromegaly compared&#xD;
           to patients with nonfunctioning pituitary adenomas.&#xD;
&#xD;
      This is a voluntary study. Adult patients with a diagnosis of acromegaly or a clinically&#xD;
      nonfunctioning pituitary tumor receiving treatment at the Emory University Pituitary center&#xD;
      will be given the opportunity to enroll in the study. Those that agree to participate will&#xD;
      need to give written informed consent. Approximately 3 tablespoons (44ml) of blood will be&#xD;
      drawn at enrollment for testing of vitamin D status and parathyroid hormone. If patients are&#xD;
      already undergoing a blood draw for standard laboratory tests, then the volume of 44ml of&#xD;
      blood will be obtained at the same time in order to avoid an additional needle stick. In&#xD;
      addition, a 24-hour urine collection will be obtained to assess the amount of calcium present&#xD;
      in the urine. Please note that medical or surgical therapy for your pituitary condition is&#xD;
      determined by your endocrinologist and/or neurosurgeon and not part of the research study.&#xD;
&#xD;
      Within 6 months after treatment for pituitary treatment is initiated, when patients return to&#xD;
      Emory University pituitary clinic for routine visit, laboratory data (vitamin D and&#xD;
      parathyroid hormone) and repeat urine studies (24 hour urine collection) will be collected.&#xD;
&#xD;
      The confidentiality will be respected in all encounters. No personal identifiers are&#xD;
      disclosed in any publications. Hard copy data will be kept securely in a locked office&#xD;
      building with limited access and electronic data will always be password protected with&#xD;
      access available to study personnel only. If abnormal results are discovered as part of&#xD;
      testing done for this study, those results will be released to the patient's primary&#xD;
      physician. All patients will be undergoing standard therapy for their pituitary disorder.&#xD;
&#xD;
      Results of this study may have important implications for future studies that are designed to&#xD;
      evaluate the mechanism of how growth hormone may increase calcitriol levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Calcitriol/PTH</measure>
    <time_frame>Baseline and 3-6 months after trreatment of pituitary condition</time_frame>
    <description>To describe baseline calcitriol/PTH status in patients with uncontrolled acromegaly, with subanalyses based on presence of hyperprolactinemia.&#xD;
To assess the change in calcitriol/PTH levels after treatment with acromegaly, with subanalyses based on type of therapy (surgical or medical).&#xD;
To evaluate the calcium and calcitriol/PTH levels in patients with acromegaly compared to patients with nonfunctioning pituitary adenomas, with subanalyses based on presence of hyperprolactinemia in either group.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">49</enrollment>
  <condition>Acromegaly</condition>
  <condition>Nonfunctioning Pituitary Tumor</condition>
  <arm_group>
    <arm_group_label>Group 1 - Acromegaly, Group 2 - control</arm_group_label>
    <description>Group 1 - Acromegaly patients, Group 2 - Nonfunctioning pituitary adenoma patients (control)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine samples obtained from subjects.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with uncontrolled acromegaly and nonfunctioning pituitary adenomas presenting to&#xD;
        the Emory University Pituitary Center for medical or surgical treatment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with acromegaly or a nonfunctioning pituitary who will receive&#xD;
             treatment for the pituitary condition.&#xD;
&#xD;
          -  Study subjects must agree to participate in this study and provide written consent.&#xD;
&#xD;
          -  Site- Emory Clinic/Emory University hospital.&#xD;
&#xD;
          -  Stage of Disease: Patients with active acromegaly that is either newly diagnosed or&#xD;
             uncontrolled on current therapy (as shown by GH/IGF-1 levels). Patients with&#xD;
             nonfunctioning pituitary adenoma in whom surgical intervention planned based on&#xD;
             current guidelines will serve as a control group.&#xD;
&#xD;
          -  Age: Study subjects must be over 18 years of age.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years old&#xD;
&#xD;
          -  Prior other diseases: Patients chronic renal disease stage 3 or worse (estimated GFR &gt;&#xD;
             60).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana Ioachimescu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asst Professor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Wongsurawat N, Armbrecht HJ, Zenser TV, Forte LR, Davis BB. Effects of hypophysectomy and growth hormone treatment on renal hydroxylation of 25-hydroxycholecalciferol in rats. J Endocrinol. 1984 Jun;101(3):333-8.</citation>
    <PMID>6610018</PMID>
  </reference>
  <reference>
    <citation>Ajibade DV, Dhawan P, Fechner AJ, Meyer MB, Pike JW, Christakos S. Evidence for a role of prolactin in calcium homeostasis: regulation of intestinal transient receptor potential vanilloid type 6, intestinal calcium absorption, and the 25-hydroxyvitamin D(3) 1alpha hydroxylase gene by prolactin. Endocrinology. 2010 Jul;151(7):2974-84. doi: 10.1210/en.2010-0033. Epub 2010 May 12.</citation>
    <PMID>20463051</PMID>
  </reference>
  <reference>
    <citation>Charoenphandhu N, Wongdee K, Krishnamra N. Is prolactin the cardinal calciotropic maternal hormone? Trends Endocrinol Metab. 2010 Jul;21(7):395-401. doi: 10.1016/j.tem.2010.02.002. Epub 2010 Mar 20.</citation>
    <PMID>20304671</PMID>
  </reference>
  <reference>
    <citation>Lancer SR, Bowser EN, Hargis GK. The effect of growth hormone on parathyroid function in rats. Endocrinology. 1976 May;98(5):1289-93.</citation>
    <PMID>1261522</PMID>
  </reference>
  <reference>
    <citation>Cook DM, Ezzat S, Katznelson L, Kleinberg DL, Laws ER Jr, Nippoldt TB, Swearingen B, Vance ML; AACE Acromegaly Guidelines Task Force. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract. 2004 May-Jun;10(3):213-25. Erratum in: Endocr Pract. 2005 Mar-Apr;11(2):144. Endocr Pract. 2008 Sep;14(6):802-3. Cook, David M [added]; Ezzat, Shereen [added]; Katznelson, Laurence [added]; Kleinberg, David L [added]; Laws, Edward R Jr [added]; Nippoldt, Todd B [added]; Swearingen, Brooke [added]; Vance, Mary Lee [added].</citation>
    <PMID>15382339</PMID>
  </reference>
  <reference>
    <citation>Ezzat S, Melmed S, Endres D, Eyre DR, Singer FR. Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab. 1993 Jun;76(6):1452-7.</citation>
    <PMID>8501150</PMID>
  </reference>
  <reference>
    <citation>Nadarajah A, Hartog M, Redfern B, Thalassinos N, Wright AD, Joplin GF, Fraser TR. Calcium metabolism in acromegaly. Br Med J. 1968 Dec 28;4(5634):797-801.</citation>
    <PMID>5702295</PMID>
  </reference>
  <reference>
    <citation>Sigurdsson G, Nunziata V, Reiner M, Nadarajah A, Joplin GF. Calcium absorption and excretion in the gut in acromegaly. Clin Endocrinol (Oxf). 1973 Jul;2(3):187-92.</citation>
    <PMID>4760543</PMID>
  </reference>
  <reference>
    <citation>Takamoto S, Tsuchiya H, Onishi T, Morimoto S, Imanaka S, Mori S, Seino Y, Uozumi T, Kumahara Y. Changes in calcium homeostasis in acromegaly treated by pituitary adenomectomy. J Clin Endocrinol Metab. 1985 Jul;61(1):7-11.</citation>
    <PMID>3839000</PMID>
  </reference>
  <reference>
    <citation>Halse J, Haugen HN. Calcium and phosphate metabolism in acromegaly. Acta Endocrinol (Copenh). 1980 Aug;94(4):459-67.</citation>
    <PMID>6254298</PMID>
  </reference>
  <reference>
    <citation>Hennessey JV, Jackson IM. Clinical features and differential diagnosis of pituitary tumours with emphasis on acromegaly. Baillieres Clin Endocrinol Metab. 1995 Apr;9(2):271-314. Review.</citation>
    <PMID>7625986</PMID>
  </reference>
  <reference>
    <citation>Brown DJ, Spanos E, MacIntyre I. Role of pituitary hormones in regulating renal vitamin D metabolism in man. Br Med J. 1980 Feb 2;280(6210):277-8.</citation>
    <PMID>7357340</PMID>
  </reference>
  <reference>
    <citation>White HD, Ahmad AM, Durham BH, Chandran S, Patwala A, Fraser WD, Vora JP. Effect of active acromegaly and its treatment on parathyroid circadian rhythmicity and parathyroid target-organ sensitivity. J Clin Endocrinol Metab. 2006 Mar;91(3):913-9. Epub 2005 Dec 13.</citation>
    <PMID>16352693</PMID>
  </reference>
  <reference>
    <citation>Lund B, Eskildsen PC, Lund B, Norman AW, SÃ¸rensen OH. Calcium and vitamin D metabolism in acromegaly. Acta Endocrinol (Copenh). 1981 Apr;96(4):444-50.</citation>
    <PMID>7211102</PMID>
  </reference>
  <reference>
    <citation>Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ. Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab. 2003 Dec;88(12):5650-5.</citation>
    <PMID>14671148</PMID>
  </reference>
  <reference>
    <citation>Chanson P, Salenave S, Kamenicky P, Cazabat L, Young J. Pituitary tumours: acromegaly. Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):555-74. doi: 10.1016/j.beem.2009.05.010. Review.</citation>
    <PMID>19945023</PMID>
  </reference>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <last_update_submitted>December 4, 2014</last_update_submitted>
  <last_update_submitted_qc>December 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Adriana Ioachimescu, MD, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Neoplasms</mesh_term>
    <mesh_term>Acromegaly</mesh_term>
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

